Britannia Life Sciences Inc.
BLSIF
$0.04
$0.000.00%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 65.91% | 7.42% | -- | -124.85% | -262.22% |
| Total Depreciation and Amortization | 4.55% | 5.61% | -- | -21.00% | -79.21% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -112.48% | -84.47% | -- | 116.29% | 298.69% |
| Change in Net Operating Assets | -98.51% | -262.07% | -- | -42.87% | -33.33% |
| Cash from Operations | -678.33% | -8,849.47% | -- | 16.82% | -84.78% |
| Capital Expenditure | -- | -- | -- | -91.49% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -5,184.13% | -186.83% | -- | -661.18% | -273.37% |
| Cash from Investing | -5,184.13% | -186.83% | -- | 89.47% | -203.62% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -28.94% | -41.23% | -- | -19.31% | 95.02% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -115.54% | 94.32% | -- | -15.96% | 140.23% |
| Foreign Exchange rate Adjustments | -89.79% | -145.74% | -- | -102.77% | 140.31% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2,440.59% | -144.76% | -- | 101.59% | 163.71% |